E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with severe sepsis |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10040047 |
E.1.2 | Term | Sepsis |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Prevention of the development of septic shock in patients with severe sepsis |
|
E.2.2 | Secondary objectives of the trial |
Mortality and survival, length of ICU and hospital stay, time until septic shock develops, organ dysfunctions, duration of mechanical ventilation and renal replacement therapy, incidence of side effects and adverse events (safety), adrenal function at baseline
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Evaluation of Posttraumatic Stress Disorder and Health-related Quality of Life
Objective: Quationnaires at hospital discharge and after 6 months
Continuation of the SepNet central blood sample storage bank for identification and validation of future biomarkers of sepsis and evaluation of genetic polymorphisms Evaluation of immune responses to low dose hydrocortisone
Objectives: blood sampling within the first 7 days after randomisation |
|
E.3 | Principal inclusion criteria |
Patients must meet ALL inclusion criteria:
1. Informed consent from patient, legal representative, proxy, or independent medical consultant.
2. In women with child bearing potential an effective contraception with a failure rate < 1 %.
3. Clinical evidence of INFECTION (may be present ≥ 48 hours) –
At least one of a-d is required.
a. Pathogenic micro-organism in blood, sputum, urine, or normally sterile body fluid
b. Identified focus of infection (e.g. ruptured bowel, purulent drainage or sputum)
c. Presence of granulocytes in normally sterile body fluid
d. Clinically suspected infection without positive culture of pathogenic microorganism (e.g. new infiltrate in chest X-ray, treated pneumonia, necrotizing fasciitis, purpura fulminans)
4. Evidence of SIRS (may be present ≥ 48 hours) –
At least two of a-d are required.
a. Fever (≥38 °C) or Hypothermia (≤ 36 °C)
b. Tachycardia (≥ 90 bpm)
c. Tachypnea (≥ 20 bpm) or hyperventilation (PaCO2 ≤ 33 mmHg [≤ 4.3 kPa], or mechanical ventilation
d. Leukocytosis (≥ 12.000 / µl) or leukopenia (≤ 4.000 / µl) or ≥ 10 % immature forms
5. Evidence of ORGAN DYSFUNCTION (may NOT be present ≥ 48 hours –
At least one organ dysfunction of a-e is required
a. Encephalopathy: Reduced vigilance, disorientation, agitation, delirium etc. in the absence of psychotropic drugs
b. Acute renal dysfunction: Oliguria: ≤ 0.5 ml/kg/h ≥ 2 h despite adequate volume replacement and/or creatinine increase > 2 x above the normal upper range, and/or need for renal replacement therapy.
c. Coagulation dysfunction: Platelets ≤ 100.000/µl or more than 30 % decrease from baseline within 24 hours. Thrombocytopenia may not be due to haemorrhage or immunologically induced.
d. Pulmonary dysfunction/hypoxemia: PaO2 ≤ 75 mmHg [≤ 10 kPa] at room air or PaO2/FiO2 ≤ 250 mmHg [≤ 33 kPa] with oxygen application. Hypoxemia may not be due to primary cardiac or pulmonary dysfunction (e.g. emphysema)
e. Microcirculatory dysfunction: Lactate > 1.5 x above the normal upper range and/or base deficit ≥ 5 mmol/l and/or metabolic acidosis with pH < 7.3 and/or depressed capillary refill/mottling and/or significant body edema (capillary leakage syndrome)
A highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner. For subjects using a hormonal contraceptive method, information regarding the product under evaluation and its potential effect on the contraceptive should be addressed [ICH-ORG 1995]
Due to the severity of the disease and hospitalisation, sexual abstinence during application of the study medication is assumed and may be regarded as an effective method of contraception, even if the investigator is not aware of an alternative mode of applied contraceptive method at the time of inclusion into the study.
|
|
E.4 | Principal exclusion criteria |
Patients will be excluded for ANY ONE of the following reasons:
I. Sepsis-induced HYPOTENSION despite adequate volume replacement defined as a mean arterial pressure (MAP) < 65 mmHg or a systolic arterial pressure (SAP) < 90 mmHg, or the use of vasopressors to keep MAP ≥ 65 mmHg or SAP ≥ 90 mmHg, IF any of these conditions persist for 4 hours ore more.
NOTE: Patients who received transiently vasopressors only during initial resuscitation (volume deficit) or had an iatrogenic-induced hypotension (e.g. intubation, bolus sedation), but are free of vasopressors and have no hypotension for at least two hours after initial resuscitation or the hypotensive event, are defined to be not in shock. It is essential that at the time of allocation of study medication, patients MAY NOT be in septic shock.
Adequate volume status is defined as a central venous pressure ≥ 8 mmHg in non-ventilated and ≥ 12 mmHg in ventilated patients, and a central venous oxygen saturation ≥ 70 %.
Vasopressor is defined as dopamine ≥ 5 µg/kg/min or any dose of epinephrine, norepinephrine, vasopressin, or other vasopressor.
II. Patients with known hypersensitivity to hydrocortison-21-hydrogensuccinate, natrium-monohydrogenphosphate , or mannitol (placebo).
III. Patients who have a glucocorticoid history AND in whom a continued glucocorticoid therapy may be indicated (e.g. > 10 mg prednisolone equivalent per day for at least 5 days within the last 3 months). Topical or inhaled glucocorticoids are NO exclusion criteria, unless there is an indication for continued systemic glucocorticoid administration.
IV. Other indications for systemic glucocorticoid therapy (e.g. asthma, COPD, anaphylaxis, autoimmune diseases)
V. DNR-order
VI. Moribund patients
VII. Pregnancy (positive pregnancy test in women with child bearing potential)
VIII. Breast feeding women
IX. Age < 18 years
X. Concomitant or previous (within the last 30 days) participation in an other interventional clinical trial
XI. Relationship to the investigator (e.g. relatives, colleagues, staff) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
28-day mortality (proportion of patients who die within 28 days from any cause)
• 90 and 180-day mortality
• ICU-mortality
• Hospital mortality
• Time to death from any cause and sepsis-related death
• Length of ICU stay
• Length of hospital stay
• Time to septic shock and/or death within 14 days
• Frequency and duration of mechanical ventilation until ICU discharge
• Frequency and duration of renal replacement until ICU discharge
• Mean total SOFA (organ dysfunction) and mean SOFA sub-scores until ICU discharge but day 14 at maximum
• Frequency of weaning failure until ICU-discharge
• Frequency and severity of muscle weakness until ICU-discharge
• Frequency of GI-bleeding within 28 days
• Frequency of secondary infections within 28 days
• Frequency of delirium until ICU-discharge
• Blood sodium level and frequency of hypernatremia (> 155 mmol/l) within 14 days
• Blood glucose level and frequency of hyperglycemia (> 150 mg/dl) within 14 days
• Other AEs or SAEs within 28 days |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 20 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial ends after follow-up (visit) of the last patient. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |